Medicare plans to provide insurance coverage for Aduhelm, a controversial Alzheimer’s treatment from drugmaker Biogen.
from the drugmaker Biogen, the Centers for Medicare & Medicaid Services announced Tuesday.
The CMS struck a cautious tone during a press call Tuesday."While there are may be a potential for promise with this treatment, there's also the potential for serious harm," CMS Chief Medical Officer Lee Fleisher said on the call. "CMS says there is kind of insufficient evidence to suggest that this drug, and other drugs like it, are reasonable and necessary," she said.
Biogen’s drug, a monoclonal antibody, is given as an infusion every four weeks. It targets a “sticky” compound in the brain known as beta-amyloid, which some scientists believe plays a role in the disease. The proposal could change substantially before it's finalized in April, but beneficiaries would be expected to be responsible for 20 percent co-payment for the treatment, which carries a list price of $28,200, Cubanski, of Kaiser Family Foundation, said.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patientsThe U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, potentially limiting access.
Baca lebih lajut »
Medicare is about to make its most important coverage decision in years. Here’s how people with Alzheimer’s and others might be affected.A controversial new drug is roiling the medical community and driving up Medicare premiums.
Baca lebih lajut »
Medicare proposes to cover controversial Alzheimer's drug with restrictionsMedicare proposes covering a costly and controversial Alzheimer's drug, with some restrictions. It could have vast consequences for patients and enrollees.
Baca lebih lajut »
Medicare limits coverage of Alzheimer’s drug with $28,000-a-year price tagBiogen’s initial launch price of $56,000 a year for Aduhelm led to an increase of nearly $22 in Medicare’s monthly “Part B” premium for outpatient care, the largest ever in dollar terms but not percentage-wise.
Baca lebih lajut »
Medicare Told to Reassess Premium Hike for Alzheimer's DrugU.S. health secretary Xavier Becerra is ordering Medicare to reassess a big premium increase facing millions of seniors this year
Baca lebih lajut »
Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drugDepartment of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Baca lebih lajut »